Abstract
Background: Observational data suggest that low 25-hyroxyvitamin D is associated with cardiovascular disease (CVD) and its risk factors include diabetes, metabolic syndrome, insulin resistance, hypertension, microalbuminuria and inflammation. We examined the differences between risk factors of CVD before and after treatment with calcitriol in type 2 diabetic patients with vitamin D deficiency.
Methods: This study was a clinical trial consisting of 119 type 2 diabetic patients. Forty three patients had vitamin D insufficiency (25 OH D less than 30 ng/dl) who underwent calcitriol treatment with 0.5 microgram per day for 8 weeks. Blood pressure, fasting blood sugar (FBS), glycosylated hemoglobin (HbA1C), lipid profile, high sensitive C-reactive protein (HsCRP), Homocysteine and albumin to creatinine ratio were measured, before and after the treatment period. Then the two sets of results were compared with each other.
Results: Following treatment with calcitriol HbA1C, total cholesterol, low density lipoprotein(LDL), high density lipoprotein(HDL) and diastolic blood pressure decreased significantly (p = 0.01, 0.01, 0.04, 0.001 and 0.04 respectively) but the changes in other parameters were not significant.
Conclusion: Replacement of vitamin D may have a beneficial effect on some of the risk factors of CVD in diabetic patients.
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title:Impact of Oral 1,25-Dihydroxy Vitamin D (Calcitriol) Replacement Therapy on Coronary Artery Risk Factors in Type 2 Diabetic Patients
Volume: 13 Issue: 4
Author(s): Shokoufeh Bonakdaran, Afsoon F. Nejad, Varasteh Abdol-Reza, Asieh Hatefi and Mohammad Shakeri
Affiliation:
Keywords: CVD, diabetes, HbA1C, HsCRP, lipids, vitamin D.
Abstract: Background: Observational data suggest that low 25-hyroxyvitamin D is associated with cardiovascular disease (CVD) and its risk factors include diabetes, metabolic syndrome, insulin resistance, hypertension, microalbuminuria and inflammation. We examined the differences between risk factors of CVD before and after treatment with calcitriol in type 2 diabetic patients with vitamin D deficiency.
Methods: This study was a clinical trial consisting of 119 type 2 diabetic patients. Forty three patients had vitamin D insufficiency (25 OH D less than 30 ng/dl) who underwent calcitriol treatment with 0.5 microgram per day for 8 weeks. Blood pressure, fasting blood sugar (FBS), glycosylated hemoglobin (HbA1C), lipid profile, high sensitive C-reactive protein (HsCRP), Homocysteine and albumin to creatinine ratio were measured, before and after the treatment period. Then the two sets of results were compared with each other.
Results: Following treatment with calcitriol HbA1C, total cholesterol, low density lipoprotein(LDL), high density lipoprotein(HDL) and diastolic blood pressure decreased significantly (p = 0.01, 0.01, 0.04, 0.001 and 0.04 respectively) but the changes in other parameters were not significant.
Conclusion: Replacement of vitamin D may have a beneficial effect on some of the risk factors of CVD in diabetic patients.
Export Options
About this article
Cite this article as:
Bonakdaran Shokoufeh, Nejad F. Afsoon, Abdol-Reza Varasteh, Hatefi Asieh and Shakeri Mohammad, Impact of Oral 1,25-Dihydroxy Vitamin D (Calcitriol) Replacement Therapy on Coronary Artery Risk Factors in Type 2 Diabetic Patients, Endocrine, Metabolic & Immune Disorders - Drug Targets 2013; 13 (4) . https://dx.doi.org/10.2174/18715303113136660047
DOI https://dx.doi.org/10.2174/18715303113136660047 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Assessment of Interleukin-18 on the Risk of Coronary Heart Disease
Medicinal Chemistry Resilience to Alzheimer's Disease: The Role of Physical Activity
Current Alzheimer Research Sex Differences and Emerging New Risk Factors for Atherosclerosis and Its Thrombotic Complications
Current Pharmaceutical Design Use of Chronic Disease Registries to Optimize Cardiovascular Health
Current Vascular Pharmacology Chest Pain, Panic Disorder and Coronary Artery Disease: A Systematic Review
CNS & Neurological Disorders - Drug Targets Antioxidant Activity of Galantamine and Some of its Derivatives
Current Medicinal Chemistry Impact of N-acetylcysteine and Etodolac Treatment on Systolic and Diastolic Function in a Rat Model of Myocardial Steatosis Induced by High-Fat-Diet
Endocrine, Metabolic & Immune Disorders - Drug Targets Hyperhomocysteinemia and Sudden Cardiac Death: Potential Arrhythmogenic Mechanisms
Current Vascular Pharmacology Molecular Mechanisms of Renal Blood Flow Autoregulation
Current Vascular Pharmacology Developing Stress Assessment forms for Thai Cancer Patients: The Thai Version of the Modified Symptoms of Stress Inventory (Modified SOSI)
Current Psychiatry Research and Reviews Translational Research in Oncology: The Need of Additional In Vitro Preclinical Testing Methods for New Drugs
Current Pharmaceutical Design Angiotensin Receptor Blockers in Hypertension and Cardiovascular Diseases
Cardiovascular & Hematological Agents in Medicinal Chemistry Patient Perspectives in OMERACT Provide an Anchor for Future Metric Development and Improved Approaches to Healthcare Delivery in Connective Tissue Disease Related Interstitial Lung Disease (CTD-ILD)
Current Respiratory Medicine Reviews The Immunosuppressive Agent FK506 Prevents Subperineurial Degeneration and Demyelination on Ultrastructural and Functional Analysis
Current Neurovascular Research Ionic Liquid as a Green Media for the One-Pot Synthesis of New α- Thiazolodepsipeptide Derivatives via a Four-Component Reaction
Letters in Organic Chemistry Anti-Inflammatory Actions of the Heme Oxygenase-1 Pathway
Current Pharmaceutical Design Patent Selections:
Recent Patents on Food, Nutrition & Agriculture Selective Serotonin Re-Uptake Inhibitors for the Treatment of Depression in Coronary Artery Disease and Chronic Heart Failure: Evidence for Pleiotropic Effects
Cardiovascular & Hematological Agents in Medicinal Chemistry Hypoxia-Inducible Factor-1 in Arterial Disease: A Putative Therapeutic Target
Current Vascular Pharmacology Nutraceutical Targeting of Placental Synthesis of Soluble Fms-Like Tyrosine Kinase- 1 (sFlt-1) as Strategy for Preventing and Controlling Pre-eclampsia
Current Pharmaceutical Design